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Bone remodeling after renal transplantation. Several studies post-transplant bone loss has increased during the last
have indicated that bone alterations after transplantation are decade, not only because of the associated increase in
heterogeneous. Short-term studies after transplantation have morbidity and the augmented risk of fractures, but alsoshown that many patients exhibit a pattern consistent with
because a better understanding of its histopathology andadynamic bone disease. In contrast, patients with long-term
the pathogenic mechanisms involved are fundamental inrenal transplantation show a more heterogeneous picture.
Thus, while adynamic bone disease has also been described in designing effective strategies for prevention and control.
these patients, most studies show decreased bone formation
and prolonged mineralization lag-time faced with persisting
bone resorption, and even clear evidence of generalized or ALTERATIONS OF BONE REMODELING
focal osteomalacia in many patients. Thus, the main alterations
Studies by Julian et al [3] showed that six monthsin bone remodeling are a decrease in bone formation and
after transplantation, patients exhibited a low bone mass,mineralization up against persistent bone resorption, suggesting
defective osteoblast function, decreased osteoblastogenesis, or decreased mineral apposition rate, and delayed mineral-
increased osteoblast death rates. Indeed, recent studies from our ization consistent with a pattern of adynamic bone dis-
laboratory have demonstrated that there is an early decrease in
ease. It has been argued that in the majority of theosteoblast number and surfaces, as well as in reduced bone
patients studied the pre-transplant bone lesions were notformation rate and delayed mineralization after transplanta-
tion. These alterations are associated with an early increase in severe, consisting of mild secondary hyperparathyroid-
osteoblast apoptosis that correlates with low levels of serum ism, and that the high doses of glucocorticoids required
phosphorus. These changes were more frequently observed in early after transplantation explain the high prevalence
patients with low turnover bone disease. In contrast, PTH
of low bone turnover [7].seemed to preserve osteoblast survival. The mechanisms of
Studies performed in patients with long-term renalhypophosphatemia in these patients appear to be independent
of PTH, suggesting that other phosphaturic factors may play transplantation (more than 3 years) and relatively nor-
a role. However, further studies are needed to determine the mal renal function are discrepant. Thus, while Velas-
nature of a phosphaturic factor and its relationship to the quez-Forero et al [6] showed that the main alterationsalterations of bone remodeling after transplantation.
were consistent with adynamic bone disease and in-
creased deposition of iron on the mineralization front,
other studies have shown decreased bone formation and
It has been well established that a rapid bone mass
prolonged mineralization lag-time in the presence of per-
loss occurs in the first six to 12 months after a successful
sisting bone resorption [4–6]. Our studies in patients withrenal transplantation [1–6], and persists, albeit at a lower
normal renal function after a mean of 7.5 years of renalrate, for many years. Thus, previous studies from our
transplantation [5] showed a mixed lesion characterizedand other laboratories have shown a low bone mineral
by an increase in bone resorption in the majority ofdensity even in patients with long-term renal transplanta-
patients, while bone formation rate was low and mineral-tion (3 to 10 or more years) and normal renal function
ization lag-time prolonged. These lesions were more se-[4–7]. Several studies indicate that the bone lesions ob-
vere in patients having less time after transplantation,served in these patients are heterogeneous and suggest
but improved with time, finally approaching normal val-that the pathogenic mechanisms underlying these alter-
ues after 10 years of transplantation. In a similar studyations are multifactorial.
in patients with long-term renal transplantation, Cueto-The interest in the bone alterations underlying the
Manzano et al [8] have also shown increased osteoclastic
resorption and decreased osteoblastic function with de-
layed mineralization and bone formation rate, suggestingKey words: post-transplant bone disease, post-transplant osteoblast
apoptosis. a mixed bone disease in the majority of patients, whereas
adynamic bone disease and secondary hyperparathyroid- 2003 by the International Society of Nephrology
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ism were observed in fewer cases. More recently, Monier- PATHOGENESIS OF POST-TRANSPLANT
BONE DISEASEFaugere et al [7] showed low bone turnover, decreased
bone formation, and prolonged mineralization in the The pathogenesis of post-transplant bone disease is
majority of patients, whereas an increase in erosion sur- multifactorial. There seems to be no doubt that pre-
face was observed in less than a quarter of the patients. transplant osteodystrophy plays an important role in the
A striking finding of the study was the presence of gener- maintenance or development of post-transplant alter-
alized or focal osteomalacia in many patients [7]. The ations of bone remodeling. Indeed, most transplant pa-
authors suggested that these findings are likely to be tients suffer different forms of pre-existing bone disease
present in the entire population of patients after trans- that may persist after transplantation. Thus, in patients
plantation. with nonsuppressible nodular parathyroid hyperplasia,
Although there are discrepancies among the findings the persistently elevated PTH levels after restoration of
described in different studies, it seems evident from the the normal renal function may play a primary role in
majority of them that the main alterations in bone re- maintaining a high bone turnover. In addition, some
modeling after renal transplantation are a decrease in patients may develop de novo secondary hyperparathy-
bone formation and mineralization in the face of persis- roidism resulting from progressive functional alterations
tent bone resorption. This produces an imbalance in of the transplanted kidney [1, 10, 11]. However, in many
remodeling favoring resorption [5–8]. Therefore, it is studies the bone histopathologic findings are heteroge-
possible that the defective bone formation may be a neous, ranging from high bone turnover to low bone
consequence of either alterations in osteoblast function, turnover [4–8] without apparent correlation to post-
decreased osteoblastogenesis, or increased osteoblast transplant serum PTH levels [5–8], suggesting that other
death rates. factors that begin to operate after transplantation play
Based on these observations, we recently examined a central role in the development of the bone alterations
the possible role of an early increase in osteoblast apo- observed in these patients.
ptosis and alterations in osteoblastogenesis, as well as Finally, we found a positive correlation between osteo-
the influence of pre-existing bone disease in the histo- blast surface and the serum levels of pre- and post-trans-
morphometric alterations in bone after transplantation plant PTH, suggesting an important role of the hormone
[9]. The studies were performed shortly after renal trans- in preserving osteoblast number and activity after trans-
plantation, a period in which patients receive high doses plantation [9]. Indeed, previous studies by Jilka et al
of glucocorticoids, and in which some of the pre-existing [25] indicate that in mice, PTH increases the lifespan
alterations of bone metabolism may still be present. Pa- of mature osteoblasts by preventing apoptosis. These
tients were subjected to bone biopsy the day of trans- findings are also in agreement with the fact that post-
plantation and within 21 to 120 days after transplanta- transplant apoptosis was rare in patients with pre-trans-
tion. The main alterations in bone histology were a plant secondary hyperparathyroidism
decrease in osteoid and osteoblast surfaces and adjusted Several studies suggest that post-transplant immuno-
bone formation rate, while the mineralization lag-time suppressive therapy constitutes a major factor in the
was prolonged. Resorption and osteoclast surfaces re- pathogenesis of post-transplant bone disease [8, 12, 13].
mained above the normal range [9]. In addition, almost The possible role of cyclosporine has been controversial.
half of the patients showed early osteoblast apoptosis in Studies in animals and humans have shown that cyclo-
post-transplant biopsies and lower osteoblast surfaces sporine causes high bone turnover [12–14]. However,
and number [9]. Osteoblast apoptosis was more fre- other studies have failed to demonstrate an effect of the
quently observed in patients with adynamic bone disease, drug on mineral and bone metabolism in renal transplant
osteomalacia, and mixed bone disease than in patients recipients [5, 7, 15]. It should be considered, however,
with high bone turnover, suggesting a pathogenic role that the role of cyclosporine in transplant patients has
of the pre-existing bone disease. Since apoptosis is a been difficult to evaluate because its effects on bone
short-lasting phenomenon, the fact that it was observed turnover may be masked by glucocorticoids.
in some post-transplant biopsies, but not in pre-trans- In the studies of Julian et al [3] and Monier-Faugere
plant biopsies, suggests that there is an increase in the et al [7], glucocorticoids appear to be the sole determi-
proportion of cells undergoing apoptosis in these pa- nant of bone volume and turnover. Thus, the cumulative
tients. Another observation of this study was a change and mean prednisone doses correlated negatively with
in osteoblast morphology, demonstrating a marked shift bone turnover, whereas there was no correlation with
toward quiescence, or inactive form from the cuboidal cyclosporine cumulative dose, and serum PTH [7]. Since
morphology of active osteoblasts, even in the presence of neither immunosupressive therapy nor biochemical and
elevated osteoid thickness in many patients, suggesting hormonal parameters, including PTH, calcitriol, and se-
rum phosphorus correlated with delayed mineralization,defective mineralization [9].
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they concluded that post-transplant bone disease is (FGF23) as one of the possible candidates that fulfills
mainly a consequence of glucocorticoid therapy [7]. the criteria for phosphatonin [25–27]. This factor induces
The mechanisms by which glucocorticoids may affect phosphaturia, hypophosphatemia, and osteomalacia in
bone metabolism are multifactorial. These drugs in- mice. However, further studies are needed to determine
crease osteoclastic resorption and decrease osteoblastic the nature of a phosphaturic factor and its relationship
activity [16]. In addition, glucocorticoids may indirectly with the alterations of bone remodeling after transplanta-
affect bone metabolism by decreasing intestinal calcium tion.
absorption, leading to an increase in PTH secretion. In summary, although the alterations of bone remodel-
There is evidence suggesting that, under normal condi- ing after transplantation are heterogeneous, most studies
tions, an important number of osteoblasts undergo apo- reflect a decrease in bone formation in the face of persis-
ptosis [17]. Furthermore, studies in mice indicate that tently elevated bone resorption. This imbalance in re-
glucocorticoids promote osteoblast and osteocyte apo- modeling favoring resorption leads to a progressive loss
ptosis and inhibit osteoblastogenesis, resulting in the defec- of bone mass and an increased risk of fracture. The
tive bone formation observed in glucocorticoid-induced mechanisms involved in these alterations include pre-
osteoporosis [18]. Therefore, it seems possible that con- existing conditions, such as the predominant state of
tinuous use of glucocorticoids represents an important bone turnover prior to transplantation. But post-trans-
pathogenic factor in the development and maintenance plant events such as the effects of glucocorticoids and
of post-transplant bone disease. Interestingly, we found the occurrence of hypophosphatemia seem to be funda-
a negative correlation between cumulative doses of glu- mental for the alterations of bone remodeling.
cocorticoid and post-transplant osteoblast surface early
after transplantation [9]. Since this is a period of maximal ACKNOWLEDGMENTS
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